Comprehensive investigation on synthetic cannabinoids: metabolic behaviour, detectability and potency testing, using 5F-APP-PICA and AMBFUBINACA as model compounds.
Ver/ Abrir
Impacto
Scholar |
Otros documentos de la autoría: Fabregat-Safont, David; Mardal, Marie; Noble, Carolina; Cannaert, Annelies; Stove, Christophe; Sancho, Juan V; Linner, Kristian; Hernandez, Felix; Ibáñez, Maria
Metadatos
Mostrar el registro completo del ítemcomunitat-uji-handle:10234/9
comunitat-uji-handle2:10234/33596
comunitat-uji-handle3:10234/33597
comunitat-uji-handle4:
INVESTIGACIONMetadatos
Título
Comprehensive investigation on synthetic cannabinoids: metabolic behaviour, detectability and potency testing, using 5F-APP-PICA and AMBFUBINACA as model compounds.Autoría
Fecha de publicación
2019-09Editor
WileyCita bibliográfica
FABREGAT-SAFONT, David; MARDAL, Marie; NOBLE, Carolina; CANNAERT, Annelies; STOVE, Christopher; SANCHO LLOPIS, Juan Vicente; LINNER, Kristian; HERNÁNDEZ HERNÁNDEZ, Félix; IBÁÑEZ MARTÍNEZ, María (2019). Comprehensive investigation on synthetic cannabinoids: metabolic behaviour, detectability and potency testing, using 5F-APP-PICA and AMBFUBINACA as model compounds. Drug testing and analysis, v. 11, n. 9, p. 1358-1368Tipo de documento
info:eu-repo/semantics/articleVersión de la editorial
https://onlinelibrary.wiley.com/doi/full/10.1002/dta.2659Versión
info:eu-repo/semantics/publishedVersionPalabras clave / Materias
Resumen
Synthetic cannabinoids (SCs) represented 45% of new psychoactive substances seizures in Europe (data from 2016). The consumption of SCs is an issue of concern due to their still unknown toxicity and effects on human ... [+]
Synthetic cannabinoids (SCs) represented 45% of new psychoactive substances seizures in Europe (data from 2016). The consumption of SCs is an issue of concern due to their still unknown toxicity and effects on human health, the great variety of compounds synthetized, and the continuous modifications being made to their chemical structure to avoid regulatory issues. These compounds are extensively metabolized in the organism and often cannot be detected as the intact molecule in human urine. The monitoring of SCs in forensic samples must be performed by the analysis of their metabolites. In this work, a workflow for the comprehensive study of SC consumption is proposed and applied to 5F‐APP‐PICA (also known as PX 1 or SRF‐30) and AMB‐FUBINACA (also known as FUB‐AMB or MMB‐FUBINACA), based not only on the elucidation of their metabolites but also including functional data using the NanoLuc approach, previously published. Both cannabinoids were completely metabolized by human hepatocytes (12 and 8 metabolites were elucidated by high resolution mass spectrometry for 5F‐APP‐PICA and AMB‐FUBINACA, respectively) and therefore suitable consumption markers are proposed. The bioassays revealed that 5F‐APP‐PICA presented lower activity than AMB‐FUBINACA at CB1 and CB2 receptors, based on the half maximal effective concentration (EC50) and the maximum response (Emax). These results are in agreement with the different intoxication cases found in the literature for AMB‐FUBINACA. [-]
Publicado en
Drug testing and analysis (2019), v. 11, n. 9Proyecto de investigación
1) Ministerio de Economía y Competitividad. Grant Number: CTQ2015‐65603‐P; 2) University Jaume I. Grant Number: UJI‐B2018‐19; 3) Ministerio de Educación, Cultura y Deporte. Grant Number: FPU15/02033; 4) University of Copenhagen. Grant Number: EST17/00024; 5) Ghent University Research Council. Grant Numbers: 01 N00814, 01 J15517Derechos de acceso
http://rightsstatements.org/vocab/CNE/1.0/
info:eu-repo/semantics/openAccess
info:eu-repo/semantics/openAccess
Aparece en las colecciones
- IUPA_Articles [306]